Daniele Focosi
Daniele Focosi is an expert in Infectiology at Azienda Ospedaliera Universitaria Pisana (Italy). As of October 2026, ScienceLeadR ranks Daniele Focosi in the top 1% of experts worldwide for Coronavirus Infections and COVID-19. Daniele Focosi has authored 382 publications, the most recent in 2026. SLR score: 1,542 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 382
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Advancing Immunization Strategies in Immunosuppressed Populations-Current Evidence, Clinical Challenges, and Future Directions. PMID 42931432 — immunization | Vaccines (Basel) | 2026 | 0 |
| Blood and Respiratory TTV Load, Anellovirus Species Distribution, and Compartment Overlap in Acute Respiratory Viral Infections. PMID 42925242 — torque teno virus, cytokines, anelloviridae, respiratory syncytial viruses, high-throughput nucleotide sequencing, blood, genome, rhinovirus, aged, viruses, infections, virus diseases | J Med Virol | 2026 | 0 |
| Chikungunya Virus: What a Transfusion Service Needs to Know. PMID 42655741 — blood safety, safety, blood, arboviruses, virology, public health, chikungunya virus, viruses, transplantation | Viruses | 2026 | 0 |
| New and novel pharmacotherapies for hemophilia A: an update. PMID 42619563 — antithrombins, hemorrhage, rna, small interfering, antithrombin iii, drug therapy, hemophilia a, therapeutics | Expert Opin Pharmacother | 2026 | 0 |
| Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. PMID 42536824 — antibodies, covid-19, viruses, antibodies, monoclonal, immunocompromised host, therapeutics, infections, plasma, virus diseases | Rev Med Virol | 2026 | 1 |
LeadR Networks
Main global connection map